Eli Lilly and Company $LLY Shares Sold by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 14,485 shares of the company’s stock after selling 525 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Eli Lilly and Company were worth $11,052,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of LLY. Vanguard Group Inc. increased its stake in Eli Lilly and Company by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after buying an additional 1,183,038 shares during the period. Laurel Wealth Advisors LLC boosted its holdings in Eli Lilly and Company by 78,621.2% in the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after purchasing an additional 11,537,661 shares during the period. Norges Bank bought a new stake in Eli Lilly and Company during the second quarter valued at $8,827,714,000. Jennison Associates LLC raised its holdings in shares of Eli Lilly and Company by 4.3% during the second quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock worth $4,246,596,000 after purchasing an additional 226,620 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Eli Lilly and Company by 2.0% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 5,359,653 shares of the company’s stock worth $4,178,010,000 after buying an additional 103,119 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly confirmed it will buy Ventyx Biosciences in an all-cash deal worth about $1.2 billion, gaining a pipeline of oral small-molecule NLRP3 inhibitors and inflammatory disease candidates that expand Lilly beyond diabetes/weight-loss. This acquisition is a clear pipeline/strategic positive. Eli Lilly to buy Ventyx Biosciences in $1.2 billion deal
• Positive Sentiment: Lilly expanded its obesity/metabolic pipeline via a multiyear partnership/licensing deal with Nimbus (reported value ~$1.3B), adding an oral obesity candidate to its development portfolio — another growth pathway beyond injectables. Boston biotech Nimbus to partner with Eli Lilly on weight-loss pill in $1.3 billion deal
• Positive Sentiment: Lilly struck a collaboration with InduPro on a next-gen cancer program worth up to $950 million, strengthening oncology exposure and long-term revenue optionality. Lilly links up with InduPro in next-gen cancer treatment deal worth up to $950M
• Positive Sentiment: Clarivate named several Lilly cardiometabolic launches among drugs to watch for 2026, highlighting continued product catalysts beyond current blockbusters. Lilly’s prospective cardiometabolic launches dominate list of drugs to watch in 2026: Clarivate
• Positive Sentiment: Analysts are bullish: Citigroup flagged ~50% upside, and several upgrades/positive notes have circulated, supporting momentum and investor confidence in Lilly’s pipeline and earnings outlook. Eli Lilly Stock (LLY) Has 50% Upside, Says Citigroup
• Neutral Sentiment: The stock printed an all-time high intraday as buyers priced in the M&A and deal flow; that’s market confirmation of the reaction but not a new fundamental. Eli Lilly stock hits all-time high of 1113.03 USD
• Negative Sentiment: Lilly faces legal pressure: the Indiana attorney general sued alleging inflated insulin pricing, a regulatory and reputational overhang that could lead to fines, settlements or policy scrutiny. Indiana sues Eli Lilly alleging insulin price-fixing scheme

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,107.54 on Thursday. The company has a 50-day moving average of $1,028.26 and a 200-day moving average of $856.98. The firm has a market cap of $1.05 trillion, a price-to-earnings ratio of 54.18, a price-to-earnings-growth ratio of 0.77 and a beta of 0.35. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,117.66.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same period last year, the firm posted $1.18 earnings per share. The firm’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is 33.86%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on LLY shares. Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Weiss Ratings restated a “buy (b-)” rating on shares of Eli Lilly and Company in a research note on Monday, December 22nd. Morgan Stanley raised their target price on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the company an “overweight” rating in a research note on Monday, November 24th. The Goldman Sachs Group upped their price target on shares of Eli Lilly and Company from $951.00 to $1,145.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Eli Lilly and Company in a research note on Monday, December 1st. Five equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $1,169.00.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.